# Edgar Filing: INTROGEN THERAPEUTICS INC - Form 8-K

# INTROGEN THERAPEUTICS INC

Form 8-K May 13, 2003

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Pursuant to Section 13 or 13(d) of the Securities Exchange Act of 1934		
Date of Report (Date of earliest event reported):	May 13, 2003	
Intro	gen Therapeutics, Inc.	
(Exact name of r	egistrant as specified in its char	rter)
Delaware	0-21291	74-2704230
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
301 Congress Aver	nue, Suite 1850, Austin, Texas	78701
(Address of princ	cipal executive offices) (Zip Co	ode)
Registrant s telephone number, including area code:	(512) 708-9310	
(Former name or form	ner address, if changed since las	st report)

#### Item 7. Financial Statements and Exhibits.

- (c) Exhibits.
- 99.1 Press Release dated May 13, 2003.

### Item 9. Regulation FD Disclosure.

## Edgar Filing: INTROGEN THERAPEUTICS INC - Form 8-K

The press release filed as an exhibit to this report is being furnished under Item 12 (Furnishing of Earnings Releases) as contemplated by SEC Release Nos. 33-8176 and 33-8216.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 13, 2003

INTROGEN THERAPEUTICS, INC

James W. Albrecht, Jr.
Chief Financial Officer

-2-

#### INDEX TO EXHIBITS

Exhibit Number	Description of Document
99.1	Press Release dated May 13, 2003.